CENTER FOR DRUG EVALUATION AND RESEARCH

APPLICATION NUMBER:

022255Orig1s000

MICROBIOLOGY REVIEW(S)

Product Quality Microbiology Review

27 March 2010

NDA: 22-255 – Resubmission, Class 2 response

Drug Product Name
Proprietary: Lacosamide Oral Syrup
Non-proprietary: (R) -2-acetomido-N-benzyl-3-methoxypropionamide
Drug Product Priority Classification: S1

Review Number: 2

Dates of Submission(s) Covered by this Review

Letter	Stamp	Review Request	Assigned to Reviewer
October 16, 2009	October 17, 2009	February 18, 2010	February 24, 2010

Submission History (for amendments only)

Submit Date(s)	Microbiology Review #	Review Date(s)
September 28, 2007	1	May 31, 2008

Applicant/Sponsor
Name: Schwarz Biosciences
Address: P.O.Box 110167, Research Triangle Park, NC 27709
Representative: Susan Tegtmeyer, Senior Manager, Reg. Affairs
Telephone: 770-970-8654 (phone), 770-970-8345 (fax)

Name of Reviewer: Vinayak B. Pawar, Ph.D.

Conclusion: The application is recommended for approval from microbiology product quality standpoint.

Product Quality Microbiology Data Sheet

A. 1. TYPE OF SUBMISSION: Original NDA

2. SUBMISSION PROVIDES FOR: A change (b) (4) in the reformulated oral solution.

3. MANUFACTURING SITE: Schwarz Pharma Manufacturing Inc., 1101 C Avenue West, Seymour, IN 47274.

4. DOSAGE FORM, ROUTE OF ADMINISTRATION AND STRENGTH/POTENCY: 10mg/mL

5. METHOD(S) OF STERILIZATION: (b) (4)

6. PHARMACOLOGICAL CATEGORY: For treatment of partial-onset seizures.

B. SUPPORTING/RELATED DOCUMENTS: NDA 22-253 & NDA 22-255

C. REMARKS: The Re-submitted NDA 22-255 (October 16, 2009) is intended to be a full response to the FDA's complete response letter dated October 28, 2008. Although there were no microbiology product quality deficiencies in the original submission, the re-submission is being reviewed due to changes made (b) (4) . During the review of the Lacosamide oral solution application in Europe, the EMEA requested the removal of (b) (4) from the formulation (June 2008). For consistency, it was also removed from the proposed US formulation. Therefore, in the re-submission, the reformulation of the oral syrup Lacosamide (SPM927) includes removal of (b) (4) and a change in (b) (4) level. The re-submission is in electronic format in EDR. Initial Quality Assessment has been filed by Martha Heinman on October 30, 2007. No IQA was filed for the re-submission.

filename: **C:\my documents\review\supplement\N022255R2**

Executive Summary

I. Recommendations

A. Recommendation on Approvability – The re-submission is recommended for approval from microbiology product quality standpoint.

B. Recommendations on Phase 4 Commitments and/or Agreements, if Approvable - NA

II. Summary of Microbiology Assessments

A. Brief Description of the Manufacturing Processes that relate to Product Quality Microbiology – (b) (4)

(b) (4)

The resubmission has a change in formulation (b) (4)

B. Brief Description of Microbiology Deficiencies – None.

C. Assessment of Risk Due to Microbiology Deficiencies – None.

III. Administrative

A. Reviewer's Signature _____

Primary Reviewer, Vinayak B. Pawar, Ph.D.

B. Endorsement Block _____

Secondary concurrence, Bryan S. Riley, Ph.D.

C. CC Block

N/A

5 Pages have been Withheld in Full immediately following this page as B4 (CCI/TS)

Application Type/Number	Submission Type/Number	Submitter Name	Product Name
NDA-22255	ORIG-1	SCHWARZ BIOSCIENCES INC	VIMPAT

This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

VINAYAK B PAWAR
03/30/2010

BRYAN S RILEY
03/31/2010
I concur.

DOCKET ALARM

Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts

Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research

With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips

Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS
Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS
Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS
Sync your system to PACER to automate legal marketing.